Price
Target price
€31.07
€31.07
1.000%
0.31
1.000%
€36.87
23.08.24 / Tradegate
WKN: 529882 / Symbol: CORT / Name: Corcept / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Corcept Therapeutics Inc. Stock
Corcept Therapeutics Inc. gained 1.000% compared to yesterday.
Corcept Therapeutics Inc. is currently one of the favorites of our community with 17 Buy predictions and no Sell predictions.
As a result the target price of 36 € shows a slightly positive potential of 15.87% compared to the current price of 31.07 € for Corcept Therapeutics Inc..
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Corcept Therapeutics Inc. | 1.000% | 0.811% | -2.449% | 5.680% | 3.567% | 74.551% | 165.193% |
Gritstone Oncology Inc | 0.530% | -7.695% | -29.843% | -71.064% | -75.985% | -93.904% | - |
Rockwell Medical Inc. | -7.540% | 12.945% | 44.605% | 24.700% | 49.942% | -50.050% | -88.377% |
Pacira Pharmaceuticals | - | 6.957% | -32.787% | -64.244% | -58.725% | -74.795% | -61.925% |
Comments
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Piper Sandler from $35.00 to $38.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $35.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat